CLYM: Advancing two antibody assets in renal and autoimmune diseases with pivotal trials and robust data flow
Two antibody programs are advancing in immune-mediated diseases, with CLYM116 showing best-in-class 12-week dosing and safety in IgAN, and budoprutug demonstrating strong efficacy in pMN and ITP. Multiple pivotal trials and data readouts are planned through 2025, supported by a strong financial pos…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.